These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26483867)

  • 1. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Takino J; Nagamine K; Hori T; Sakasai-Sakai A; Takeuchi M
    World J Hepatol; 2015 Oct; 7(23):2459-69. PubMed ID: 26483867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
    Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
    Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of Intracellular TAGE and the TAGE-RAGE-ROS Axis in the Onset and Progression of NAFLD/NASH.
    Sakasai-Sakai A; Takeda K; Takeuchi M
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.
    Takeuchi M; Takino J; Sakasai-Sakai A; Takata T; Ueda T; Tsutsumi M; Hyogo H; Yamagishi S
    World J Hepatol; 2014 Dec; 6(12):880-93. PubMed ID: 25544875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review.
    Sakasai-Sakai A; Takata T; Takino JI; Takeuchi M
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells.
    Sakasai-Sakai A; Takata T; Takeuchi M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
    Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
    Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.
    Kan H; Yamagishi S; Ojima A; Fukami K; Ueda S; Takeuchi M; Hyogo H; Aikata H; Chayama K
    J Clin Lab Anal; 2015 Nov; 29(6):480-4. PubMed ID: 25252033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
    Nagaoki Y; Hyogo H; Ando Y; Kosaka Y; Uchikawa S; Nishida Y; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Okamoto W; Kawaoka T; Tsuge M; Hiramatsu A; Miki D; Imamura M; Takahashi S; Chayama K; Aikata H
    BMC Gastroenterol; 2021 Jul; 21(1):306. PubMed ID: 34332532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Hepatic Stellate Cell Death by Toxic Advanced Glycation End-Products.
    Takino JI; Sato T; Nagamine K; Sakasai-Sakai A; Takeuchi M; Hori T
    Biol Pharm Bull; 2021; 44(1):112-117. PubMed ID: 33390537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma.
    Iida H; Aihara T; Ikuta S; Yamanaka N
    Oncol Lett; 2015 Oct; 10(4):2233-2238. PubMed ID: 26622825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of Toxic Advanced Glycation End-Products Induces Cytotoxicity and Inflammation in Hepatocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells.
    Kikuchi C; Sakasai-Sakai A; Okimura R; Tanaka H; Takata T; Takeuchi M; Matsunaga T
    Biol Pharm Bull; 2021; 44(10):1399-1402. PubMed ID: 34602548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-B, non-C hepatocellular carcinoma (Review).
    Nishikawa H; Osaki Y
    Int J Oncol; 2013 Nov; 43(5):1333-42. PubMed ID: 23969900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent trend of clinical features in patients with hepatocellular carcinoma.
    Nagaoki Y; Hyogo H; Aikata H; Tanaka M; Naeshiro N; Nakahara T; Honda Y; Miyaki D; Kawaoka T; Takaki S; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Takahashi S; Chayama K
    Hepatol Res; 2012 Apr; 42(4):368-75. PubMed ID: 22151896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.
    Takeuchi M
    Diagnostics (Basel); 2016 Jun; 6(2):. PubMed ID: 27338481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of non-B, non-C liver cirrhosis in Japan.
    Suzuki Y; Ohtake T; Nishiguchi S; Hashimoto E; Aoyagi Y; Onji M; Kohgo Y;
    Hepatol Res; 2013 Oct; 43(10):1020-31. PubMed ID: 23347437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
    Fernando DH; Forbes JM; Angus PW; Herath CB
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
    Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
    World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.